Next report date
Report period
H1 2024
EPS estimate
0.06HKD
Revenue estimate
654.65 MHKD
0.05HKD
45.62 MHKD
1.07 BHKD
905.83 M
About KINDSTAR GLOBALGENE TECHNOLOGY INC
Sector
Industry
CEO
Shi Ang Huang
Website
Headquarters
Wuhan
Founded
2007
ISIN
KYG5262E1044
FIGI
BBG00ZF3HWC7
Kindstar Globalgene Technology, Inc. is an investment holding company, which engages in the provision of clinical testing services. It operates through the following segments: Hematology Testing, Genetic Diseases and Rare Diseases, Infectious Diseases, Oncology, Neurology, Maternity-Related Diseases, COVID-19 Related Testing, Routine Testing, and Others. The Others segment includes testing services for research and development projects, and others and miscellaneous services. The company was founded on August 24, 2007 and is headquartered in Wuhan, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 9960 is 1.60 HKD — it has increased by 2.56% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange KINDSTAR GLOBALGENE TECHNOLOGY INC stocks are traded under the ticker 9960.
KINDSTAR GLOBALGENE TECHNOLOGY INC is going to release the next earnings report on Aug 14, 2024. Keep track of upcoming events with our Earnings Calendar.
9960 stock is 3.23% volatile and has beta coefficient of 0.47. Check out the list of the most volatile stocks — is KINDSTAR GLOBALGENE TECHNOLOGY INC there?
9960 earnings for the last quarter are 0.05 HKD per share, whereas the estimation was 0.03 HKD resulting in a 66.67% surprise. The estimated earnings for the next quarter are 0.04 HKD per share. See more details about KINDSTAR GLOBALGENE TECHNOLOGY INC earnings.
KINDSTAR GLOBALGENE TECHNOLOGY INC revenue for the last quarter amounts to 532.51 M HKD despite the estimated figure of 570.91 M HKD. In the next quarter revenue is expected to reach 629.63 M HKD.
Yes, you can track KINDSTAR GLOBALGENE TECHNOLOGY INC financials in yearly and quarterly reports right on TradingView.
9960 stock has risen by 5.96% compared to the previous week, the month change is a 13.48% rise, over the last year KINDSTAR GLOBALGENE TECHNOLOGY INC has showed a 8.57% decrease.
9960 net income for the last quarter is −2.91 M HKD, while the quarter before that showed 49.74 M HKD of net income which accounts for −105.86% change. Track more KINDSTAR GLOBALGENE TECHNOLOGY INC financial stats to get the full picture.
Today KINDSTAR GLOBALGENE TECHNOLOGY INC has the market capitalization of 1.49 B, it has increased by 0.65% over the last week.
Like other stocks, 9960 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KINDSTAR GLOBALGENE TECHNOLOGY INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KINDSTAR GLOBALGENE TECHNOLOGY INC technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KINDSTAR GLOBALGENE TECHNOLOGY INC stock shows the neutral signal. See more of KINDSTAR GLOBALGENE TECHNOLOGY INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KINDSTAR GLOBALGENE TECHNOLOGY INC EBITDA is 7.43 M HKD, and current EBITDA margin is 0.77%. See more stats in KINDSTAR GLOBALGENE TECHNOLOGY INC financial statements.